Literature DB >> 22547626

Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery.

Mercedes Gonzalez-Juarrero1, Lisa K Woolhiser, Elizabeth Brooks, Mary Ann DeGroote, Anne J Lenaerts.   

Abstract

Here we describe an experimental murine model that allows for aerosolized antituberculosis drug efficacy testing. Intrapulmonary aerosol delivery of isoniazid, capreomycin, and amikacin to mice with pulmonary infection of Mycobacterium tuberculosis demonstrated efficacy in reducing pulmonary bacterial loads similar to that seen by standard drug delivery methods, even when lower concentrations of drugs and fewer doses were used in the aerosolized drug regimens. Interestingly, intrapulmonary delivery of isoniazid also reduced the bacterial load in the spleen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547626      PMCID: PMC3393411          DOI: 10.1128/AAC.00464-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Airways delivery of rifampicin microparticles for the treatment of tuberculosis.

Authors:  S Suarez; P O'Hara; M Kazantseva; C E Newcomer; R Hopfer; D N McMurray; A J Hickey
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

2.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization.

Authors:  P O'Hara; A J Hickey
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

3.  Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Veronica Gruppo; Lisa K Woolhiser; Ian M Orme; Janet C Gilliland; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

4.  Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.

Authors:  Vasu V Sethuraman; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

Review 5.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  José A Caminero; Giovanni Sotgiu; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Lancet Infect Dis       Date:  2010-09       Impact factor: 25.071

6.  Optimisation of inhaled tuberculosis therapies and implications for host-pathogen interactions.

Authors:  Anthony J Hickey; Amit Misra; Brian D Robertson
Journal:  Tuberculosis (Edinb)       Date:  2010-11-26       Impact factor: 3.131

7.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.

Authors:  S Suarez; P O'Hara; M Kazantseva; C E Newcomer; R Hopfer; D N McMurray; A J Hickey
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

8.  Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Pavan Muttil; Danielle Padilla; Ding Xu; Jian Liu; Miriam Braunstein; David N McMurray; Anthony James Hickey
Journal:  AAPS J       Date:  2010-04-27       Impact factor: 4.009

9.  Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice.

Authors:  Adrian G Rosas-Taraco; David M Higgins; Joaquín Sánchez-Campillo; Eric J Lee; Ian M Orme; Mercedes González-Juarrero
Journal:  Tuberculosis (Edinb)       Date:  2010-12-31       Impact factor: 3.131

10.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

View more
  11 in total

1.  Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice.

Authors:  Chetan Rathi; Pradeep B Lukka; Santosh Wagh; Richard E Lee; Anne J Lenaerts; Miriam Braunstein; Anthony Hickey; Mercedes Gonzalez-Juarrero; Bernd Meibohm
Journal:  Tuberculosis (Edinb)       Date:  2018-12-31       Impact factor: 3.131

Review 2.  Phenazine Antibiotic-Inspired Discovery of Bacterial Biofilm-Eradicating Agents.

Authors:  Robert W Huigens; Yasmeen Abouelhassan; Hongfen Yang
Journal:  Chembiochem       Date:  2019-10-02       Impact factor: 3.164

3.  Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.

Authors:  Michael A Lyons; Anne J Lenaerts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-05-31       Impact factor: 2.745

Review 4.  Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.

Authors:  Miriam Braunstein; Anthony J Hickey; Sean Ekins
Journal:  Pharm Res       Date:  2019-10-24       Impact factor: 4.200

Review 5.  Clinical experimentation with aerosol antibiotics: current and future methods of administration.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Konstantinos Porpodis; Dionysios Spyratos; Kosmas Tsakiridis; Haidong Huang; Qiang Li; J Francis Turner; Robert Browning; Wolfgang Hohenforst-Schmidt; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2013-10-02       Impact factor: 4.162

6.  Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection.

Authors:  Sasha J Rose; Mary E Neville; Renu Gupta; Luiz E Bermudez
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

7.  The Activity of a Hexameric M17 Metallo-Aminopeptidase Is Associated With Survival of Mycobacterium tuberculosis.

Authors:  Andre F Correa; Izabela M D Bastos; David Neves; Andre Kipnis; Ana P Junqueira-Kipnis; Jaime M de Santana
Journal:  Front Microbiol       Date:  2017-03-27       Impact factor: 5.640

8.  Host Directed Therapy for Chronic Tuberculosis via Intrapulmonary Delivery of Aerosolized Peptide Inhibitors Targeting the IL-10-STAT3 Pathway.

Authors:  Rashmi Upadhyay; Andrea Sanchez-Hidalgo; Carol J Wilusz; Anne J Lenaerts; Jennifer Arab; Joanna Yeh; Karen Stefanisko; Nadya I Tarasova; Mercedes Gonzalez-Juarrero
Journal:  Sci Rep       Date:  2018-11-09       Impact factor: 4.379

9.  Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux.

Authors:  Richard E Lee; Julian G Hurdle; Jiuyu Liu; David F Bruhn; Tanja Matt; Michael S Scherman; Bernd Meibohm; Erik C Böttger; Anne J Lenaerts; Pavan K Vaddady; Zhong Zheng; Jianjun Qi; Rashid Akbergenov; Sourav Das; Dora B Madhura; Chetan Rathi; Ashit Trivedi; Cristina Villellas; Robin B Lee; Samanthi L Waidyarachchi; Dianqing Sun; Michael R McNeil; Jose A Ainsa; Helena I Boshoff; Mercedes Gonzalez-Juarrero
Journal:  Nat Med       Date:  2014-01-26       Impact factor: 53.440

10.  Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent.

Authors:  Mary A De Groote; Thale C Jarvis; Christina Wong; James Graham; Teresa Hoang; Casey L Young; Wendy Ribble; Joshua Day; Wei Li; Mary Jackson; Mercedes Gonzalez-Juarrero; Xicheng Sun; Urs A Ochsner
Journal:  Front Microbiol       Date:  2018-09-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.